M&A Deal Summary |
|
|---|---|
| Date | 2021-02-01 |
| Target | Viela Bio |
| Sector | Life Science |
| Buyer(s) | Horizon Therapeutics |
| Sellers(s) | HBM Partners AG |
| Deal Type | Add-on Acquisition |
| Deal Value | 3.1B USD |
| Advisor(s) | Goldman Sachs (Financial) Mintz Levin Cohn Ferris Glovsky and Popeo PC (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2005 |
| Sector | Life Science |
| Employees | 2,100 |
| Revenue | 3.2B USD (2021) |
Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 11 |
| Sector (Life Science) | 10 of 11 |
| Type (Add-on Acquisition) | 7 of 7 |
| State (Maryland) | 1 of 1 |
| Country (United States) | 9 of 9 |
| Year (2021) | 1 of 2 |
| Size (of disclosed) | 1 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-04-02 |
Curzion Pharmaceuticals
San Diego, California, United States Curzion Pharmaceuticals, Inc. is a development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825). Curzion Pharmaceuticals was founded in 2019 and is based in San Diego, California. |
Buy | $45M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-06-17 |
OPKO Health - Sterile Fill & Finish Manufacturing Facility
Waterford, Ireland OPKO Health - Sterile Fill & Finish Manufacturing Facility engages in the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale. |
Buy | $65M |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 19 of 35 |
| Sector (Life Science) | 18 of 32 |
| Type (Add-on Acquisition) | 1 of 5 |
| State (Maryland) | 1 of 1 |
| Country (United States) | 15 of 27 |
| Year (2021) | 1 of 10 |
| Size (of disclosed) | 2 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-15 |
Farmalisto
Bogotá, Colombia Farmalisto is a technology healthcare platform in Latin America that connects providers and users of the healthcare system to enhance value creation and delivery to end customers. The company has operations in Mexico, Colombia, and Chile. Farmalisto is expanding its services to become a partner of choice for pharmaceutical companies in logistics, marketing and disease management. Farmalisto was founded in 2013 and is based in Bogotá, Colombia. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-02-11 |
Antiva Biosciences
Redwood City, California, United States Antiva Biosciences is a developing novel topical therapies to treat pre-cancerous lesions caused by HPV, before they progress to cervical cancer. Antiva Biosciences was founded in 2012 and is based in Redwood City, california. |
Buy | - |
